Glibornuride

Glibornuride is a sulfonylurea antidiabetic drug used in the management of type 2 diabetes. It is classified under the second-generation sulfonylureas, a class of drugs known for their insulin-secretagogue action.

Mechanism of Action

Glibornuride works by stimulating the release of insulin from the pancreas. It binds to the sulfonylurea receptor (SUR1) on the pancreatic beta cells, leading to the closure of the ATP-sensitive potassium channel. This results in the depolarization of the cell membrane and the opening of the voltage-gated calcium channels. The influx of calcium triggers the release of insulin.

Pharmacokinetics

After oral administration, glibornuride is absorbed from the gastrointestinal tract. It is extensively metabolized in the liver and excreted in the urine and feces. The half-life of glibornuride is approximately 10 hours.

Side Effects

The most common side effects of glibornuride include hypoglycemia, nausea, vomiting, diarrhea, and allergic skin reactions. Severe hypoglycemia can lead to seizures, coma, and even death if not treated promptly.

Contraindications

Glibornuride is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. It should also not be used in patients with severe renal impairment or hepatic impairment due to the risk of prolonged hypoglycemia.

Interactions

Glibornuride may interact with other drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs), beta-blockers, and alcohol, which can increase the risk of hypoglycemia. On the other hand, drugs like corticosteroids and thyroid hormones may decrease the hypoglycemic effect of glibornuride.

See Also

• Sulfonylurea
• Type 2 diabetes
• Insulin

• 
  Glibornuride structure
• 
  Glibornuride synthesis